<DOC>
	<DOCNO>NCT02153476</DOCNO>
	<brief_summary>Evaluate safety efficacy ophthalmic intravitreal injection ALG-1001 human subject symptomatic focal vitreomacular adhesion</brief_summary>
	<brief_title>A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion</brief_title>
	<detailed_description />
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Symptomatic focal vitreomacular adhesion 2 . Vitreomacular traction syndrome 3 . Stage 1 2 macular hole , ≤ 350 µm 4 . BCVA 20/25 Early Treatment Diabetic Retinopathy Study ( ETDRS ) bad study eye 5 . BCVA 20/800 ETDRS good fellow eye 6 . Male female subject , 18 year age old 7 . Signed Informed Consent 1 . High myope &gt; 8.0 D spherical equivalent 2 . History prior vitrectomy study eye 3 . History photocoagulation retina study eye 4 . Macular hole study eye &gt; 350 µm 5 . Subjects epiretinal membrane study eye 6 . Subjects broad VMA , define VMA &gt; 1500 µm 7 . Subjects proliferative Diabetic Retinopathy ( DR ) , neovascular Agerelated Macular Degeneration ( AMD ) , retinal vascular occlusion study eye 8 . Subjects aphakia study eye 9 . Subjects uncontrolled glaucoma 10 . Subjects lenticular zonular instability 11 . Subjects prior ocular surgery intravitreal injection study eye within 90 day study enrollment 12 . Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>